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Poster Session II S3472 - 41).The cumulative incidence(CI) of severe acute GvHD(grade
II-IV) was 7% at 100 days.3-yr CI of chronic GvHD was 25%.3-
yr OS and PFS was 69% and 66% for sibling vs 42%(p 5 0.08)
and 41%(p 5 0.14) for unrelated donors.3-yr NRM and RR was
14% and 25% for sibling vs 31%(p 5 0.15) and 28%(p 5 0.27) for
unrelated donors.Outcomes for patients who had high-risk(HR) fea-
tures prior to transplant(poor risk cytogenetics,FLT3 ITD muta-
tion,previous MDS,secondary AML) were compared to outcomes
of those with standard risk(SR) disease.The HR group(n 5 37) had
OS and PFS at 3 yrs of 50% and 47% vs 60%(p 5 0.13) and
60%(p 5 0.1) for SR group(n 5 33).3-yr NRM and RR was 21%
and 25% in the HR group vs 23%(p 5 0.19) and 24%(p 5 0.18)
in the SR group(p 5 0.19).The 23 patients $60 yrs(20 unrelated
and/or HR) had a 3 yr OS of 38% and PFS of 38%. In conclusion,
many patients withHRAMLwho attain CRmaintain durable remis-
sions following RIC allo-HSCT with the FMC regimen. Although
outcomes are marginally less good than seen in patients with SR
AML receiving RIC transplant, they are much better than would
be achieved with current chemotherapy regimens.The low NRM
in sibling allo-HSCT together with the relatively low RR support
further exploration of FMC conditioned allo-HSCT in all patients
with SR AML with a matched sibling donor.
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PRACTICE VARIATION IN PHYSICIAN REFERRAL FOR ALLOGENEIC HE-
MATOPOIETIC CELL TRANSPLANTATION
Pidala, J.1, Craig, B.2, Lee, S.J.3, Majhail, N.4, Quinn, G.2, Anasetti, C.1
1Moffitt Cancer Center, Tampa, FL; 2Moffitt Cancer Center; 3Fred
Hutchinson Cancer Research Center; 4University of Minnesota
Hematologic malignancy patients who are not referred by their
primary Hematologist or Medical Oncologist suffer disparate access
to allogeneic hematopoietic cell transplantation (HCT). However,
systematic investigation into physician, system, and patient factors
relevant to this decision making is lacking. Accordingly, we surveyed
a nationally representative random sample of practicing Hematolo-
gists/Medical Oncologists identified through the AMA Masterfile.
The survey content was organized in three sections: (I) Vignette
based decision making according to best-worst scaling; (II) examina-
tion of physician, system and patient factors relevant to decision
making; and (III) respondent socio-demographic information. A
modified Dillman approach was utilized to encourage survey re-
sponse rate. From 1,200 surveyed, a total of 113 physicians
responded. Of these, 68% were male, 62% identified as White/
non-Hispanic, 79% practiced in non-academic settings, and 80% re-
ported spending 75-100% of their professional effort in clinical care.
From best-worst scaling data provided by physicians in response to
clinical vignettes, we detected significantly increased odds for non-
HCT referral according to age (age 60 vs. 30, OR 8.3, 95% CI
5.9-11.7, p\ 0.0001), race (African American vs. Caucasian, OR
2.4, 95%CI 1.9-2.9, p\0.0001), and insurance coverage (no cover-
age vs. coverage, OR 6.9, 95%CI 5.2-9.1, p\ 0.0001). Four attri-
bute-specific Wald tests reject equivalence in odds ratios across the
four diseases (MDS, ALL, CML, AML) at a p-value less than 0.05,
indicating condition-specific variability. Physician (perception of
HCT risks), system (insurance coverage), and patient (age, social
support, co-morbid illness) factors were strongly endorsed by re-
spondents as important determinants of their HCT referral prac-
tices. The majority (64%) of physicians indicated that patients do
not have equal access to HCT consultation. Qualitative comments
provided even greater clarity to perceived barriers to HCT referral,
largely focused on lack of insurance coverage and need for increased
education of practicing Hematologists/Medical Oncologists on tim-
ing and indication for HCT referral. These data speak to important
factors relevant to HCT referral practices, and highlight several op-
portunities for education and intervention to reduce current dispar-
ities in access to HCT.
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ALLOGENEIC STEM CELL TRANSPLANTATION IN SECONDARY ACUTEMY-
ELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME: OHSU EXPERI-
ENCE
Perets Avraham, G.1, Meyers, G.1, Kovacsovics, T.1, Curtin, P.T.2,
Leis, J.F.3, Bains, T.1, Lemieux, A.1, Maziarz, R.T.1 1Oregon Healthand Science University, Portland, OR; 2UC San Diego, La Jolla, CA;
3Mayo clinic College of Medicine, Scottsdale, AZ
Therapy related acute myeloid leukemia (t-AML) and myelodys-
plastic syndrome (t-MDS) have poor outcomes with conventional
chemotherapy. The only curative treatment is allogeneic hematopoi-
etic cell transplantation (HCT). Secondary AML evolving from
MDS (s-AML) has a similar poor prognosis with conventional anti-
leukemia therapies.
In this retrospective study, the transplant outcomes of 91 adult pa-
tients with t-AML (n 5 19), t-MDS (n 5 19) and s-AML (n 5 53)
treated with allogeneic HCT at OHSU from January 1997 to De-
cember 2010 were assessed.
Themedian age of patientswas 55 years (range: 21-72).Median age
for t-AML, t-MDS, and s-AMLwas 51, 59, and 56 years, respectively.
Poor risk cytogenetics were found in 18% of t-MDS pts and 38% of
the AML pts. Donors were mostly matched unrelated (61%), and
a myeloablative regimen was used for conditioning in 68% of the pa-
tients. Two-yearoverall survival (OS) and relapse incidencewere 44%
and 43%, respectively, for all cohorts. NRMwas 13% at 100 days and
33% at 2 years. s-AML patients had significantly improved OS com-
pared to t-AML and t-MDS patients (HR5 0.5, p5 0.02).
Four adverse risk factors impact on DFS and OS in t-AML/MDS
pts (Litzow, Blood 2010). Outcomes in our s-AML patients were as-
sessed for these factors: age . 35 years; poor-risk cytogenetics; t-
AML not in remission or advanced t-MDS; and donor other than
an HLA-identical sibling or a partially or well-matched unrelated
donor. One-year event-free survival for our subjects with 0-1, 2, or
3-4 of these risk factors was 83%, 63%, and 34%, respectively
(p5 0.01), but OS was not different (p5 0.28). However, pre-trans-
plant KPS # 80; intermediate or poor cytogenetics; and URD mis-
matched or other relative donor impacted with one-year OS for
subjects with 1, 2, or 3 of these risk factors 5 62%, 24%, and
33%, respectively (p 5 0.04).
In conclusion, the CIBMTR scoring system for t-AML/MDS was
not fully validated in our t-MDS, t-AML, and s-AML patients, but
appeared overall consistent.
However, performance status, rather than age, was more predic-
tive for OS.
Also, s-AML had improved OS compared to t-AML and t-MDS
patients, suggesting that these are biologically different diseases.
These data also indicate the need for the identification of prognos-
tic factors for secondary AML/MDS patients, to permit accurate
prediction of allogeneic HCT outcomes in this unique patient
population.
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IMPROVED OUTCOME OF ELDERLY PATIENTS AFTER REDUCED INTEN-
SITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Perets Avraham, G.1, Bains, T.1, Lemieux, A.1, Slater, S.1,
Kovacsovics, T.1, Curtin, P.2, Gajewski, J.1, Meyers, G.1,
Maziarz, R.T.1 1Knight Cancer Institute, Oregon Health and Science
University, Portland, OR; 2UCSD Moores Cancer Center, La Jolla, CA
Advanced age has been associated with higher mortality after mye-
loablative (MA) allogeneic hematopoietic cell transplantation
(HCT). Reduced intensity conditioning (RIC) and non myeloabla-
tive (NM) regimens have been developed to expand allogeneic
HCT to the aging population. A retrospective analysis of patients
aged 60 and older was performed and outcome of patients trans-
planted with MA, RIC and NM regimens were assessed.
159 patients transplanted between January 1998 and December
2010 for hematological malignancies were analyzed. 41 patients un-
derwent MA, 100 patients underwent RIC and 18 patients under-
went NM conditioned HCT. 62 patients (39%) had a matched
related donor, 67 (42%) had a matched unrelated donor and 30
(19%) had a mismatch donor HCT.
Overall survival (OS) was significantly influenced by conditioning
regimen (p 5 0.03). One year OS was 59%, 30% and 28% for RIC,
NM and MA group respectively. 3 year OS was significantly better
for RIC at 26% vs. 15% for MA (p5 0.02). There was no significant
difference in the progression free survival (PFS) and relapse rate be-
tween the three groups. There was trend towards significance for
non relapse mortality (NRM) based on conditioning regimen (p 5
0.07) and 100 day NRM was 11%, 3.5% and 6% for MA, RIC and
NM respectively.
S348 Poster Session IIRisk factors for outcomeswere analyzed and includedHematopoi-
etic cell transplantation comorbidity index (HCT-CI) score (Sorror,
Blood 2005), relapse risk score (Kahl, Blood 2007) and risk stratifica-
tion by age groups.110 patients (69%) had low or standard relapse
risk score while 49 (31%) had high score. 26 patients (16%) had
HCT- CI score of 0, 48 patients (30%) had score of 1-2, 48(30%)
had score of 3-4 and 32 (20%) had score of 5 or above.
Increasing HCT-CI score had a significant impact on OS in both
univariate and multivariate analysis (p\0.05). HCT-CI of 1-2, 3-4
and 5 plus was prognostic for OS (HR 2.6, 2.9 and 3.6; p 5 0.006,
0.005 and 0.001 respectively).For PFS, high relapse risk score was
prognostic (HR 7.8, p 5 0.001) but increasing HCT-CI score lost
significance.Risk stratification by age groups (60-65, 66-70 and 70
plus) did not show any prognostic implication on either PFS or OS.
Our results support the use of RIC HCT as a potentially curative
treatmentmodality for elderly patients, and as well support the prog-
nostic value ofHCT-CI score. Elderly patients with high scores (.5)
may not benefit fromundergoingHCTevenwithRIC orNMHCT.
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BLAST PERCENTAGE PRIOR TO TRANSPLANTATION IS THE STRONGEST
PREDICTIVE FACTOR FOR SURVIVAL AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT (HSCT) IN PATIENTS WITH MYELODYS-
PLASTIC SYNDROME (MDS)
Jimenez, A.M.1, Rich, E.S.1, Nathan, S.1, Maciejewski, J.1,
Shammo, J.M.1, Katz, D.1, Braun, E.1, Hashmi, S.2, Fung, H.C.1
1Rush University Medical Center, Chicago, IL; 2West Suburban Hospital,
Chicago, IL
Background: Allogeneic hematopoietic stem-cell transplantation
(HSCT) is the only curative treatment for patients (pts) with myelo-
dysplastic syndromes (MDS) or secondary acute myeloid leukemia
(sAML)with long-term survival rates between 25% and 70%.Disease
stage at timeof transplantationhasbeenstrongly correlatedwith trans-
plant outcomes; current data suggests that achieving a low pre-trans-
plant tumor burden is critical for a successful allograft. We sought
to retrospectively identify the relationship between pre-transplant
blast percentage and clinical outcomes following HSCT inMDS pts.
Methods: We conducted a retrospective review of pts with MDS
who received an allogeneic HSCT in our institution from 1998 to
2010. We previously reported the impact of clinical characteristics
and treatment on outcomes in this patient population.We quantified
the pre-transplant marrow burden on all pts with available pathol-
ogy. Bone marrow biopsy was performed prior to allogeneic
HSCT and pts’ blast burden was quantified as low or high on the ba-
sis of blast percentage (\5% or $5% respectively).
Results: 35 MDS pts were transplanted at our institution between
1998 and 2010. Median age was 51 years (range: 24-66); male to fe-
male ratio 1:1; matched related donor 46% (n5 16); matched unre-
lated donor 54% (n 5 19). Cytogenetic risk group by IPSS: good,
40% (n5 14), intermediate, 37% (n5 13), poor, 23% (n5 8). Graft
source was mobilized peripheral blood in 80% (n 5 28) and bone
marrow in 20% of pts (n5 7). Information on marrow blast percent-
age prior to transplant was available for 32 pts; survival was 53% at 1
year and 40% at 2 years in this group. Survival at one year was supe-
rior for pts with low blast burden compared to those with$5%blasts
(68% vs. 30%, respectively p: 0.036). Among the 17 pts alive at 1
year, 77% had low blast burden (vs. only 40% in those pts who didn’t
survive past day +365). Blast percentage prior to transplant also pre-
dicted for survival on multivariate analysis (p: 0.042).
Conclusions: Our retrospective analysis identified blast percentage
as an independent predictor of clinical outcomes in MDS pts under-
going HSCT. Our results are consistent with the current literature.
Prospective evaluation of multiple clinical variables in a larger patient
population is warranted to better characterize prognostic factors. The
role of cytoreductive therapy prior to transplant in order to achieve
a low blast burden should be further evaluated in this setting.
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THE EFFECT OF KIRS EXPRESSION PROFILE IN DONOR/RECIPIENT
PAIRS IN HLA IDENTICAL SIBLING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Tang, X., Wei, X., Feng, Y., Zhu, Z., He, J., Xu, Y. First Affiliated Hos-
pital of Soochow University, Jiangsu Institute of Hematology, Suzhou,
Jiangsu, ChinaObjective: We investigated the distribution characteristics of KIRs
expression profile in donor/recipient pairs with acute leukemia (AL)
receiving HLA-identical sibling hematopoietic stem cell transplan-
tation (sib-HSCT). We further explored the effect of KIRs expres-
sion profile in donor/recipient pairs on clinical outcome.
Methods: The genotypes of donor/recipient KIRs were determi-
nated by polymerase chain reaction- sequence specific primer
(PCR-SSP) for 80 pairs of donor/recipient receiving HLA-identical
sibling hematopoietic stem cell transplantation.
Results: 1. In 80 pairs of donor/recipient: (i) the KIRs were com-
pletely identical in 57.5% of donor/recipient pairs; (ii) the donors’
KIRs contained the recipients’ in 13.75% pairs; (iii) the recipients’
KIRs contained the donors’ in 17.5% of pairs; (iv) the KIRs were
completely different in 11.25% pairs. The graft versus host (GVH)
direction KIR-matched group was 75%. The percentage of group
donor B/X and group donor A/A was 50%, respectively. 2.Compar-
ing the patients fromGVH direction KIR-matched and mismatched
group, the incidence of acute (a) GVHD was 60% and 30%, respec-
tively (p5 0.0222), and 2-year OS was 62.96% and 94.12%, respec-
tively (p 5 0.0492). Particularly, grade III-IV aGVHD rate of
KIR-matched group was higher than that of non-KIR matched
group(15% vs 0%). 3. Donor B/X group had a higher 2-year OS
and 2-year relapse-free survival (RFS) compared with donor A/A
group (89.23% vs 49.57%, p 5 0.0159, and 90% vs 59.71%, p 5
0.0239, respectively). Patients with three or less aKIRs had a lower
2-year OS (58.9% vs 92.44%, p 5 0.0338) and a lower RFS
(65.14% vs 92.59%, p 5 0.0398), compared with patients with
more aKIR.
Conclusions: Donor KIR genotype appears to have a direct impact
on aGVHD, OS and RFS. Therefore, donor KIR genotype should
be evaluated as an outcome predictor of the HLA-identical sib-
HSCT.390
COMPARABLE SURVIVAL AFTER UNRELATED AND RELATED ALLOGE-
NEIC STEM CELL TRANSPLANTATION PERFORMED AT COMMUNITY CAN-
CER CENTERS
Khaled, Y., Solh, M., Zehngebot, L., Zakari, A., Reynolds, R., Castillo, R.,
Alemany, C., Reddy, V. Florida Cancer Institute, Orlando, FL
The outcomes after unrelated donor hematopoietic stem cell
transplantation (MUD HCT) have improved over the past decade
with survival equivalent to related donors (RD) HCT. Although
MUD HCT is becoming more available in community cancer cen-
ters, there is very limited literature available about the outcomes of
MUDHCT outside the academic setting. To study the above ques-
tion, we performed a retrospective analysis of the outcomes of 56
consecutive patients that underwent HCT (30 MUD, 26 RD) be-
tween August 2007 and July 2010 at our community cancer center.
All patients had a minimum follow up of one year post HCT. There
was no statistical difference between MUD and RD recipients
(Table 1). Conditioning regimens used were Fludarabine/Melpha-
lan in 13 patients (3 MUD & 10 RD), Busulfan based in 28 patients
(19 MUD & 9 RD), Fludarabine/TBI in 10 patients (5 MUD & 5
RD), Cytoxan/TBI in 2 patients (1 MUD & 1 RD) and other in 3
patients (2 MUD & 1 RD). Graft versus Host Disease (GVHD)
prophylaxis regimens used were Tacrolimus/Methotrexate in FIC
HCT recipients and Cyclosporine/Mycophenolate mofetil in
RIC/NMA HCT recipients. MUD HCT recipients received addi-
tional Thymoglobulin (4.5 mg/Kg). Median time to neutrophils en-
graftment was 14 days for RD and 13 days for MUD. The
cumulative incidence of acute GVHD (grade I-IV) was 60% for
MUD and 54% for RD. The cumulative incidence of chronic
GVHD was comparable between both groups of 63% and 72%
for MUD and RD respectively.
With median duration follow up of 2 years, there was no statistical
difference in overall survival (OS) at one and 2 years of 57% and 40%
for MUD recipients versus 65% and 54% for RD recipients respec-
tively (p 5 0.48). Similarly, disease free survival (DFS) at 1 and 2
years was 50% and 36% versus 50% and 22% for MUD and RD re-
cipients respectively (p5 0.24). There were more relapses in RD re-
cipients with cumulative incidence of 34% and 59% at 1 and 2 years
respectively compared to 23% at 1 and 2 years in MUD recipients.
Non relapse mortality (NRM) at day 100 was 10% and 8% for
